1	Insight into risk associated phenotypes behind COVID-19 from phenotype genome-
2	wide association studies
3	
4	Zhongzhong Chen ^{1,2,*} , Koichi Matsuda ²
5	¹ Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai
6	Jiao Tong University, Shanghai 200062, China
7	² Department of Computational Biology and Medical Sciences, Graduate school of
8	Frontier Sciences, the University of Tokyo, Tokyo, Japan
9	
10	*Address Correspondence to:
11	Zhongzhong Chen, Department of Urology, Shanghai Children's Hospital, School of
12	Medicine, Shanghai Jiao Tong University; Shanghai, 200062, China
13	Email: <u>zhongzhongchen@gmail.com</u>
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30 NO	TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 SUMMARY

Long COVID presents a complex and multi-systemic disease that poses a significant global public health challenge. Symptoms can vary widely, ranging from asymptomatic to severe, making the condition challenging to diagnose and manage effectively. Furthermore, identifying appropriate phenotypes in genome-wide association studies of COVID-19 remains unresolved. This study aimed to address these challenges by analyzing 220 deep-phenotype genome-wide association data sets (159 diseases, 38 biomarkers and 23 medication usage) from BioBank Japan (BBJ) (n=179,000), UK Biobank and FinnGen (n=628,000) to investigate pleiotropic effects of known COVID-19 risk associated single nucleotide variants. Our findings reveal 32 different phenotypes that share the common genetic risk factors with COVID-19 ($p < 7.6 \times 10^{-11}$), including two diseases (myocardial infarction and type 2 diabetes), 26 biomarkers with seven categories (blood cell, metabolic, liver-related, kidney-related, protein, inflammatory and anthropometric), and four medications (antithrombotic agents, HMG CoA reductase inhibitors, thyroid preparations and anilides). As long COVID continues to coexist with humans, our results highlight the need for targeted screening to support specific vulnerable populations to improve disease prevention and healthcare delivery. Keywords: Long COVID, SARS-CoV-2, SNP, genetic risk, phenotype

Long COVID, also known as "post-acute sequelae of COVID-19", has been identified 60 as the next public health concern. This debilitating illness is estimated to affect more 61 62 than 200 symptoms (1), and may occur in about 12.5% (1/8) people with COVID-19 in the general population (2). The current diagnostic and treatment options are inadequate, 63 and the underlying biological mechanisms need to be further addressed (1). Through 64 genome-wide association studies (GWASs), more than 40 single nucleotide variants 65 66 (SNPs) involving 35 genes have been identified as potential contributors to susceptibility to SARS-CoV-2 infection or risk of severe COVID-19 disease (3). While 67 translational studies of GWAS findings may provide novel insights into 68 pathophysiology, there remains limited understanding of the pleiotropic effects between 69 70 genetic predisposition, complications, biomarkers and medications for guiding long-71 term follow-up and life care of COVID-19 patients.

72 Phenome-wide association studies (PheWASs) based on population have opened up new avenues for formulating effective biomedical hypotheses. In this study, we 73 74 delved into the pleiotropic loci of known single nucleotide variants (SNPs) (3) that represent either susceptibility to SARS-CoV-2 infection or risk of severe COVID-19 75 disease. To do this, we analyzed 220 deep-phenotype genome-wide association data 76 sets with deep-phenotype information, comprising 159 diseases, 38 biomarkers and 23 77 78 medication usage from BioBank Japan (BBJ) (n=179,000), UK Biobank and FinnGen $(n_{total}=628,000)$ (4). 79

First, using a comprehensive PheWAS analysis of the genome-wide landscape, we 80 have identified two genetic associations with myocardial infarction and type 2 diabetes 81 that indicate a potential link to COVID-19 infection. Our diagnosis code-focused 82 PheWAS (Figure 1) revealed a significant association between rs912805253 at the 83 OASI locus and myocardial infarction (MI) (ICD-10 code I21/I22/I23/I24/I25) in both 84 the BBJ and European populations [BBJ population: odds ratio (OR) = 1.09, 95%85 confidence interval (CI) = 1.06-1.12, $p = 3.3 \times 10^{-11}$; European population: OR = 1.04, 86 95% CI = 1.02-1.07, $p = 3.4 \times 10^{-4}$]. 87

88 When combining subjects both from BBJ and European population, the OR for 89 rs912805253 with MI was 1.07 (95% CI = 1.05-1.08, $p = 1.3 \times 10^{-12}$). Furthermore,

90 rs912805253 was also significantly associated with type 2 diabetes (T2D) (ICD-10 code E11) in both populations [BBJ population: odds ratio (OR) = 1.04, 95% 91 confidence interval (CI) = 1.02-1.06, $p = 3.7 \times 10^{-5}$; European population: OR = 1.05, 92 95% CI = 1.03-1.07, $p = 2.4 \times 10^{-8}$]. When combining subjects from both population, the 93 OR for rs912805253 with T2D was 1.05 (95% CI = 1.03-1.06, $p = 5.6 \times 10^{-12}$). Clinical 94 95 studies (cohorts) have suggested and increased risk of long-term cardiovascular 96 outcomes (5) and type 2 diabetes (6) after COVID-19 infection, but their genetic risk 97 factors are still unclear. Our findings shed light on the potential genetic link between COVID-19 infection and these diseases, providing a valuable contribution to this field. 98 99 Second, our findings provide compelling evidence of shared genetic risk factors 100 across 26 clinical lab-measurement, particularly among seven blood cell biomarkers 101 (neutrophil, monocyte, white blood cell, eosinophil, hemoglobin, hematocrit and red 102 blood cell), two metabolic biomarkers (total cholesterol and triglycerides), one liverrelated biomarker (aspartate transaminase) and one protein biomarker (total protein). 103 104 Based on our analysis using the clinical lab-measurement PheWAS, we identified 86 significant associations between 12 SNPs and 26 biomarkers (7.6×10^{-11}) (Figure 1). 105 Among these biomarkers, blood cell measurements emerged as one of the top 106 associated categories, followed by metabolic, liver-related, kidney-related, protein, 107 108 inflammatory, anthropometric. Within the blood cell type category, neutrophil (NEU) $(rs912805253, p = 4.9 \times 10^{-18}; rs879055593, p = 1.9 \times 10^{-29}; rs9411378, p = 1.1 \times 10^{-22};$ 109 rs1819040, $p = 5.0 \times 10^{-16}$; rs11540822, $p = 3.1 \times 10^{-19}$; rs143334143, $p = 8.7 \times 10^{-20}$), 110 monocyte (MON) (rs912805253, $p = 8.2 \times 10^{-69}$; rs879055593, $p = 9.7 \times 10^{-50}$; 111 rs9411378, $p = 1.3 \times 10^{-45}$; rs17763537, $p = 7.0 \times 10^{-15}$; rs73064425, $p = 2.2 \times 10^{-16}$; 112 rs10490770, $p = 3.8 \times 10^{-15}$), and white blood cell (WBC) (rs912805253, $p = 1.8 \times 10^{-28}$; 113 rs879055593, $p = 9.4 \times 10^{-35}$; rs9411378, $p = 9.7 \times 10^{-24}$; rs11540822, $p = 1.2 \times 10^{-45}$; 114 rs143334143, $p = 1.2 \times 10^{-46}$) were associated with five or more COVID-19 risk 115 116 associated SNPs. Among metabolic biomarkers, total cholesterol (TC) (rs912805253, $p = 1.1 \times 10^{-47}$; rs879055593, $p = 4.5 \times 10^{-86}$; rs9411378, $p = 3.2 \times 10^{-47}$; rs11540822, $p = 1.1 \times 10^{-47}$; rs11540824, $p = 1.1 \times 10^{-47}$; rs11540824, p =117 6.2×10^{-11}) and triglycerides (TG) (rs879055593, $p = 6.9 \times 10^{-17}$; rs9411378, p =118 3.4×10^{-11} ; rs11540822, $p = 2.8 \times 10^{-12}$; rs143334143, $p = 1.2 \times 10^{-12}$) were each 119

120 associated with four SNPs. Finally, aspartate transaminase (AST) in the kidney-related category was enriched for six COVID-19 risk associated SNPs (rs912805253, p =121 3.3×10^{-34} ; rs879055593, $p = 5.4 \times 10^{-49}$; rs9411378, $p = 2.5 \times 10^{-43}$; rs1819040, $p = 2.5 \times 10^{-43}$; rs18190, $p = 2.5 \times 10^{-43}$; rs18190, p =122 4.3×10^{-16} ; rs11540822, $p = 1.3 \times 10^{-14}$; rs143334143, $p = 1.1 \times 10^{-14}$). The identification 123 of shared genetic risk factors across multiple clinical lab-measurements highlights the 124 125 importance of understanding the interplay between various biological pathways and 126 how they contribute to COVID-19 severity. By analyzing an individual's genetic profile and clinical lab-measurements, healthcare providers may be able to better predict the 127 patient's risk of developing severe symptoms or long-term complications from COVID-128 129 19. These findings could help inform treatment decisions and prioritize high-risk 130 patients for early intervention.

131 Third, in our PheWAS analysis of medication usage, we found that antithrombotic agents (rs912805253, $p = 3.6 \times 10^{-12}$; rs879055593, $p = 4.1 \times 10^{-11}$), HMG CoA reductase 132 inhibitors (rs912805253, $p = 2.8 \times 10^{-28}$; rs879055593, $p = 2.5 \times 10^{-45}$), thyroid 133 preparations (rs11540822, $p = 3.7 \times 10^{-17}$; rs143334143, $p = 1.3 \times 10^{-16}$), and anilides 134 (rs1819040, $p = 4.6 \times 10^{-12}$) have shared genetic risk factors with COVID-19 (Figure 1). 135 This suggests that individuals with a genetic predisposition to these medications may 136 be more vulnerable to severe COVID-19 symptoms. This findings highlight the 137 138 importance of personalized treatment and management of COVID-19 based on an individual's genetic background. Furthermore, the discovery of common genetic risk 139 factors between certain medications and COVID-19 opens up new possibilities for 140 141 developing targeted therapies. By identifying the underlying genetic mechanisms, researchers could develop new medications that could modify these risk factors and 142 potentially improve patient outcomes. In the future, the personalized approach to 143 COVID-19 treatment and the development of new medications may greatly enhance 144 our ability to combat this pandemic. 145

The current diagnostic and treatment protocols for long COVID are inadequate to fully comprehend its overlap with other diseases, the variable onset of symptoms, as well as the effects of vaccinations (1). Definitive diagnostic criteria for long COVID have yet to be established (7). Establishing a comprehensive surveillance system is

150	imperative to effectively manage the ongoing presence of long COVID. Vaccination			
151	remains the ultimate protection against SARS-CoV-2 infection. To address these gaps,			
152	our study characterized the risk associated phenotypes behind COVID-19 by			
153	incorporating PheWASs data sets from BBJ and European biobank (4), and summarized			
154	data from published and peer-reviewed GWAS articles on COVID-19 (3). We identified			
155	32 significant associated phenotypes across two diseases, 26 biomarkers, and four			
156	medications after conservative Bonferroni multiple testing correction ($p < 7.6 \times 10^{-11}$).			
157	Our findings provide valuable insights into the pathophysiology of COVID-19 infection,			
158	its complications, treatment, genetic risk prediction and lifelong care. This study could			
159 160	aid in the identification and development of new treatment options.			
160	Acknowledgments: The authors wish to thank Dr. Aiko Kurosaka from the University			
162	of Tokyo for providing valuable insights during our analysis.			
163				
164	Funding: This work was supported by grants from the Japan China Sasakawa Medical			
165	Fellowship.			
166				
167				
168	the project; all authors reviewed the paper and contributed to scientific content.			
169				
170	Competing interests: The authors have no conflicts of interest to disclose.			
171				
172	References			
173				
174	1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,			
175	mechanisms and recommendations. Nat Rev Microbiol. 2023;1-14.			
176	2. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines			
177	Corona Research I. Persistence of somatic symptoms after COVID-19 in the			
178	Netherlands: an observational cohort study. Lancet. 2022; 400:452-461.			
179	3. Karlsen TH. Understanding COVID-19 through genome-wide association			
180	studies. Nat Genet. 2022; 54:368-369.			

6

181	4.	Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic
182		associations for 220 human phenotypes. Nat Genet. 2021; 53:1415-1424.

- 183 5. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of
 184 COVID-19. Nat Med. 2022; 28:583-590.
- 185 6. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a
 186 cohort study. Lancet Diabetes Endocrinol. 2022; 10:311-321.
- 187 7. Quinn KL, Razak F, Cheung AM. Diagnosing post-COVID-19 condition (long
- 188 COVID) in adults. CMAJ. 2023; 195:E78-E79.
- 189
- 190
- 191
- 192
- . . .
- 193
- 194
- 195
- 196

197 Figures and Figure legends




Figure 1. The landscape of associations with diseases, clinical measures (biomarkers) and medication usage for genetic risk loci from COVID-19 GWASs. The association results only considered the SNPs reached the Bonferroni-corrected threshold of $<7.6\times10^{-11}$, using -log10(p value). Risk locus, candidate genes and their representation for SARS-CoV-2 infection and severe COVID-19 with complications from Karlsen's summary (*3*). Abbreviations and full names for diseases and biomarkers: MI, myocardial infarction; T2D, type 2 diabetes; NEU, neutrophil; MON, monocyte; WBC, white blood cell; EOS, eosinophil; Hb, hemoglobin; Ht, hematocrit; RBC, red blood cell; LYM, lymphocyte; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; Alb, albumin; PLT, platelet; TC, total cholesterol; TG, triglycerides; LDLC, LDL-cholesterol; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, γ -glutamyl transpeptidase; ALT, alanine aminotransferase; sCr, serum creatinine; BUN, blood urea nitrogen; TP, total protein; CRP, C-reactive protein.

198

199